Cargando…

PB1921: IS CHEMOIMMUNOTHERAPY (CIT) HISTORY IN THE FIRST LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKAEMIA?

Detalles Bibliográficos
Autores principales:	Parbutt, Catherine, Munir, Talha, Varghese, Abraham Mullasseril
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429840/ http://dx.doi.org/10.1097/01.HS9.0000974508.28366.1d

Ejemplares similares

PB1859: DEFINING T-CELL POPULATIONS IN CHRONIC LYMPHOCYTIC LEUKAEMIA
por: Mora, A., et al.
Publicado: (2022)

PB1877: ADJUSTING SURVIVAL DATA FOR TREATMENT CROSSOVER IN THE ELEVATE-TN TRIAL BY USING A HISTORICAL COHORT OF PATIENTS TREATED WITH CHEMOIMMUNOTHERAPY IN FRONT-LINE CHRONIC LYMPHOCYTIC LEUKEMIA
por: Gaitonde, P., et al.
Publicado: (2022)

PB1940: REAL-LIFE EXPERIENCE OF THE IMMUNE RECONSTITUTION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA AND SMALL LYMPHOCYTIC LYMPHOMA TREATED WITH IBRUTINIB.
por: Pérez, Belén Olivares, et al.
Publicado: (2023)

PB1854: NEXT GENERATION SEQUENCING APPROACHES IN CHRONIC LYMPHOCYTIC LEUKAEMIA: FINDINGS FROM EXTERNAL QUALITY ASSESSMENT
por: Cartwright, A., et al.
Publicado: (2022)

PB1932: RETROSPECTIVE STUDY OF BURDEN OF INFECTION IN PATIENTS WITH AND WITHOUT SECONDARY IMMUNODEFICIENCY DISEASE FOLLOWING DIAGNOSIS OF CHRONIC LYMPHOCYTIC LEUKAEMIA
por: Davids, Matthew, et al.
Publicado: (2023)

PB1867: PURINE ANALOGS ON HAIRY CELL LEUKAEMIA TREATMENT
por: Gomes, G., et al.
Publicado: (2022)

PB1872: ANTIBODY RESPONSES AFTER COVID-19 VACCINATION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA, EITHER TREATED OR NAÏVE. A MONOCENTRIC EXPERIENCE.
por: Innocenti, I., et al.
Publicado: (2022)

PB1779: DEVELOPING NOVEL SYNERGISTIC DRUG COMBINATIONS WITH VENETOCLAX IN ACUTE MYELOID LEUKAEMIA
por: Harrigan, R., et al.
Publicado: (2022)

PB1901: KARYOTYPIC PROFILE OF CHRONIC MYELOID LEUKAEMIA DIAGNOSED AT TERTIARY LEVEL IN AFGHANISTAN.
por: Haidary, A. M., et al.
Publicado: (2022)

PB1888: EFFICACY OF FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA: A BAYESIANNETWORK META-ANALYSIS.
por: Chanan-Khan, A., et al.
Publicado: (2022)

PB1820: THE EFFECT OF CONVENTIONAL CHEMOTHERAPY AFTER EXITING QUIESCENT STATE IN ACUTE MYELOID LEUKAEMIA
por: Láinez-González, Daniel, et al.
Publicado: (2023)

PB1973: MOLECULAR PATTERNS OF RESPONSE AFTER FRONTLINE TREATMENT IN CHRONIC MYELOID LEUKAEMIA (CML).
por: Fernandez-Leyva, Harberth
Publicado: (2023)

PB1944: INDIVIDUALS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA SHOW IMPAIRED HUMORAL BUT NORMAL CELLULAR IMMUNE RESPONSES AFTER RECEIVING A COMPLETE VACCINATION SCHEDULE AGAINST SARS-COV-2
por: Sánchez-Menéndez, Clara, et al.
Publicado: (2023)

PB1756: EPIDEMIOLOGY OF ACUTE LYMPHOBLASTIC LEUKAEMIA: A RETROSPECTIVE 6-YEAR SINGLE CENTRE EXPERIENCE
por: Kociaj, Jora, et al.
Publicado: (2023)

PB1899: OUTCOMES OF PATIENTS UNDERGOING TREATMENT FOR ACUTE MYELOID LEUKAEMIA SHOWING HIGH DEGREE OF PREDICTIVE ACCURACY ON THE EUROPEAN LEUKAEMIA NET (ELN) POST-REMISSION TREATMENT SCORE
por: Richardson, Michelle, et al.
Publicado: (2023)

PB1875: TREATMENT OF YOUNGER PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA IN TUNISIA: FCR STILL STANDARD FOR FIRST-LINE THERAPY
por: Miled, W., et al.
Publicado: (2022)

PB2328: CHRONIC LYMPHATIC LEUKAEMIA (CLL) ASSOCIATED TO ACQUIRED FACTOR V INHIBITOR. A CASE REPORT.
por: Porro Camarero, A., et al.
Publicado: (2022)

PB1827: TWO-LEVEL INHIBITION OF HEDGEHOG SIGNALLING PATHWAY TO EXIT QUIESCENT STATE IN ACUTE MYELOID LEUKAEMIA
por: Láinez-González, Daniel, et al.
Publicado: (2023)

PB1921: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TAMIBAROTENE/AZACITIDINE VERSUS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS (SELECT-MDS-1)
por: DeZern, A., et al.
Publicado: (2022)

PB1960: SARS-COV-2 OMICRON VARIANT INFECTION AND COVID-19 IN PERSONS WITH CHRONIC MYELOID LEUKAEMIA IN CHINA
por: Cheng, Fang, et al.
Publicado: (2023)

PB1883: IMPLANTATION AND LONG-TERM USE OF PERIPHERALLY-INSERTED CENTRAL CATHETER ARE SAFE IN PATIENTS WITH ACUTE PROMYELOCYTIC LEUKAEMIA
por: Szotkowski, Tomáš, et al.
Publicado: (2023)

PB1751: RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKAEMIA (R/R ALL) IN A SINGLE-CENTRE PAEDIATRIC POPULATION
por: Gomes, Guadalupe Ferreira, et al.
Publicado: (2023)

PB1858: INFLUENCE OF INFLAMMATION ON ANGIOGENIC FACTORS IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Mitrović Ajtić, O., et al.
Publicado: (2022)

PB1978: PATIENT-CENTREDNESS IS PIVOTAL IN A PROSPECTIVE DOSE REDUCTION TRIAL OF TYROSINE KINASE INHIBITORS IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA
por: Djodikromo, Melissa, et al.
Publicado: (2023)

PB2490: NEUTROPHIL TO LYMPHOCYTE RATIO AND PLATELET TO LYMPHOCYTE RATIO IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A MONOCENTRIC STUDY
por: Tounsi, Haifa, et al.
Publicado: (2023)

PB1869: IGHV REPERTOIRE FEATURES IN KAZAKHSTAN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS
por: Klodzinskiy, A., et al.
Publicado: (2022)

PB1793: NEUTROPHIL TO LYMPHOCYTE RATIO AS A PROGNOSTIC FACTOR IN AML AND MDS
por: Van Oorschot, V., et al.
Publicado: (2022)

PB2392: MRNA IDENTIFICATION OF TIGIT IN PERITUMORAL LYMPHOCYTES IN CLASSICAL HODGKIN DISEASE
por: Annibali, Ombretta, et al.
Publicado: (2023)

PB2454: DEVELOPMENT OF A PROGNOSTIC MODEL FOR SURVIVAL OF MIXED PHENOTYPE ACUTE LEUKAEMIA PATIENTS TREATED WITH ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Tong, Keting, et al.
Publicado: (2023)

PB2296: THE PROGNOSTIC ROLE OF NEUTROPHIL TO LYMPHOCYTE RATIO AND PLATELET TO LYMPHOCYTE RATIO IN COVID-19 PATIENTS: A MONOCENTRIC STUDY
por: Boufrikha, W., et al.
Publicado: (2022)

PB1868: COMPARISON OF MYELOBLAST CELL PERCENTAGE IN INVESTIGATIONS FOR ACUTE MYELOID LEUKAEMIA INCLUDING FLOW CYTOMETRY, BONE MARROW ASPIRATION AND BONE MARROW TREPHINE
por: Iftikhar, Naml
Publicado: (2023)

PB1892: INCREASED INCIDENCE OF SRSF2 MUTATION WITH AGE INDICATING CLONAL HAEMATOPOIESIS IN PATIENTS WITH ACUTE MYELOID LEUKAEMIA: A SINGLE-CENTER EXPERIENCE
por: Richardson, Michelle, et al.
Publicado: (2023)

PB1870: COVID - 19 IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: HOSPITAL MORALITY PREDICTORS
por: Kochneva, O., et al.
Publicado: (2022)

PB2207: NEUTROPHIL–TO-LYMPHOCYTE RATIO IS AN EARLY SCREENING TOOL FOR DIAGNOSIS OF POLYCYTHEMIA VERA
por: Yoon, Seug Yun, et al.
Publicado: (2023)

PB2461: CONDITIONING REGIMEN AND SUBPOPULATION COMPOSITION OF AUTOGRAFT LYMPHOCYTES IN PATIENTS WITH MULTIPLE MYELOMA
por: Kostroma, Ivan, et al.
Publicado: (2023)

PB1950: CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): REAL-WORLD DATA FROM LEBANON
por: Nasr, Lewis, et al.
Publicado: (2023)

PB1744: THE RATIO OF ABSOLUTE LYMPHOCYTE COUNT AT INTERIM OF THERAPY TO ABSOLUTE LYMPHOCYTE COUNT AT DIAGNOSIS PREDICTS SURVIVAL IN ACUTE LYMPHOBLASTIC LEUKEMIA
por: Faiza, Talbi, et al.
Publicado: (2023)

PB1786: COMPARISON OF OPTICAL GENOME MAPPING WITH STANDARD OF CARE TESTING TO INVESTIGATE GENOMIC ABNORMALITIES IN LEUKAEMIAS: THE EXPERIENCE OF THE CENTRAL AND SOUTH GENOMIC LABORATORY HUB, UK
por: Muraru, M., et al.
Publicado: (2022)

PB1873: EFFECTS OF LENALIDOMIDE MAINTENANCE IN CHRONIC LYMPHOCYTIC LEUKEMIA: A TRIAL-SEQUENTIAL ANALYSIS
por: Lee, C.-H., et al.
Publicado: (2022)

PB2253: NEUTROPHIL TO LYMPHOCYTE RATIO (NLR) AS A PREDICTOR OF SEVERE COVID-19 ON ADMISSION
por: Ababou, M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s7g7udon11mit9uii0g2e7402n